RLV Relevium Technologies Inc

Montreal, QC -- December 27, 2018 -- InvestorsHub NewsWire -- Relevium Technologies Inc. TSX.V:"RLV", OTCQB: "RLLVF" and Frankfurt: "6BX")

By Jeff Nielson, Stockhouse

By now, hemp is clearly on the radar of cannabis investors – for several reasons. First, the hemp sub-species of cannabis actually has many more commercial/industrial applications than the marijuana sub-species.

Second, as cannabis laws are normalized around the world, hemp is already legal (and available to be commercialized) in many more markets than marijuana, for a very important reason. Hemp contains negligible levels of THC, the cannabinoid in marijuana that produces mild psychoactive effects.

However, hemp is especially rich in cannabidiol (CBD), leading to the third reason that cannabis investors are becoming more and more interested in hemp: the dramatic surge in consumer and investor interest in products containing CBD. One Company that is moving to capitalize on these opportunities is Relevium Technologies Inc. (TSX: RLV, OTCQB: RLLVF).

Relevium is now familiar to the Stockhouse audience, having been covered in several previous feature articles. For cannabis investors who are new to RLV, they may want to check out recent coverage of the launch of Relevium’s nutraceutical distribution deal with Walmart.
 

Now the Company has more news. On December 13, 2018; RLV announced the launching of its Leefylyfe™ brand of organically sourced “full spectrum” hemp CBD products in the UK – on a pre-order basis. While hemp is on the radar of cannabis investors, the UK market for cannabis probably is not.

This is because the UK is an emerging cannabis jurisdiction. On November 1, 2018; medicinal cannabis use became officially legal in the United Kingdom. Relevium is wasting no time in jumping into this market. With its population of 66.5 million people, the UK is now one of the single largest markets for medicinal cannabis in the world.

RLV’s organic hemp CBD nutraceuticals are perfectly timed to enter this market as the people of this nation (for the first time) look to obtain the known health benefits from cannabinoid consumption, most specifically, cannabidiol. Several exclusive formulations of Leefylyfe™ are planned for launch in 2019, with the Company also targeting additional EU markets to extend Leefylyfe™ sales.

Opening up further possibilities for Leefylyfe™ products is the pending passage of the U.S. Farm Bill 2018, which includes a provision to legalize hemp for commercial purposes within the United States, at the national level.

Relevium’s Chief Marketing Officer, Abis Hussein put this news into a strategic context for investors.

The launch of LeefyLyfe™ is consistent with our focus on creating new revenue streams, diversifying the product offering and continuing to elevate our trusted brands. The company is actively integrating Phyto-cannabinoids into its OTC business to provide bring the natural goodness of Hemp to its portfolio and trusted Health and Wellness products.
 
Leefylyfe™ products are produced by a local supplier in Europre. BGX E-Health LLC, Relevium’s wholly-owned subsidiary based in Orlando, Florida, is currently testing a complete line of dietary supplements derived from cannabis, with an initial focus on hemp.

BGX E-Health is also the producer of RLV’s “Bioganix®” brand portfolio, which includes dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals. Relevium’s brands are already available from some of the world’s largest retailers, including Amazon.com and Walmart.com.
 
Aurelio Useche, CEO of Relevium shared these additional insights.
 
The entire Relevium team is proud and excited to launch LeefyLyfe™ on a pre-order basis. Our product strategy is to source locally in Europe, from GMP and Certified Organic producers, a Hemp product that is natural and rich in cannabinoids while respecting the THC threshold that is legally acceptable in the region.  [emphasis mine]
 
It is this last factor that gives hemp-derived CBD products a regulatory (and marketing) advantage as Relevium looks to extend distribution of Leefylyfe™ across Europe. Several EU jurisdictions still have extremely strict import and consumer restrictions on any cannabis products with significant THC content.
 
By sourcing its CBD from organic hemp, Relevium can be an early mover in many of these jurisdictions, as Europe catches up to North America as a market for cannabis products. As a trusted producer of nutraceutical products, and through sourcing its CBD products from organic hemp, the Company is confident that it can achieve broad market penetration with its new Leefylyfe™ product line.
 
Globally, the market for dietary health supplements is projected to soar to over $278 billion by 2024. CBD-based nutraceuticals have obvious potential to claim a significant share of this market. As investors look to capitalize on opportunities in this space, Relevium Technologies is turning heads with both its development of distribution channels and new product offerings.

releviumtechnologies.com

FULL DISCLOSURE: This is a paid article of Stockhouse Publishing.

Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Mar 2024 to Apr 2024

Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Apr 2023 to Apr 2024